Coya Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
Company: Coya Therapeutics, Inc.
Filing Date: September 15, 2026
Reporting Period: Current Report (Item 8.01 Other Events)
Business Focus: Biopharmaceutical company developing COYA 302, a combination of proprietary low-dose IL-2 and CTLA-4 Ig, for the treatment of amyotrophic lateral sclerosis (ALS).
Key Financial Metrics
This filing is a Current Report on Form 8-K regarding a clinical trial milestone. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes and Clinical Milestones
- Enrollment Milestone: The 100th patient has been enrolled in the Phase 2/3 ALSTARS Trial (NCT07161999).
- Study Design: Randomized, multi-center, double-blind, placebo-controlled study targeting approximately 120 subjects.
- Regimen: Subjects are randomized 1:1:1 to two dosing regimens of COYA 302 or placebo for a 24-week double-blind phase, followed by a potential 24-week extension.
- Primary Endpoint: Change in disease severity measured by the ALSFRS-R total score from baseline to Week 24.
Guidance, Outlook, and Risks
- Timeline Outlook: Based on current trends, the Company anticipates completing full enrollment of 120 participants in time to report topline data in early Q2 of 2027.
- Forward-Looking Statements: The filing includes statements regarding the potential benefits, safety, and timing of data for COYA 302, as well as the Company's cash runway.
- Risks: Actual results may differ due to known and unknown risks, including clinical trial outcomes and regulatory approvals. Detailed risk factors are referenced in the Company's Annual Report on Form 10-K for the year ended December 31, 2025.
Investor Verification Checklist
- Verify the actual enrollment rate against the projected timeline for Q2 2027 topline data.
- Review the "Risk Factors" section in the most recent Form 10-K for details on clinical trial uncertainties and cash runway.
- Monitor future filings for updates on the safety and tolerability data from the 24-week double-blind phase.
- Confirm the status of the FDA Fast Track designation for COYA 302 mentioned in the forward-looking statements.